From development to commercialization, Tempus provides a novel approach to companion diagnostic partnership

As one of the leaders pioneering real-world data, Tempus’ robust clinico-genomics database can be used in tandem with trial sequencing data to set up control arms, compare trial data to real-world data, and generate clinically-meaningful comparator data throughout the trial. Tempus’ sequencing data covers DNA tumor/normal, RNA transcriptome, and key immunotherapy metrics, allowing for a more holistic view to stratify likely responders and refine clinical biomarkers.

Tempus’ robust clinico-genomics database, including 400,000+ clinical-molecular records, can be used in tandem with trial sequencing data to help refine clinical biomarkers and improve program success rates.

Tempus provides an established, validated platform to help reduce development time and costs associated with companion diagnostic development and approval. Tempus’ in-house regulatory affairs team has extensive FDA and industry experience to support our partners through submission.

Tempus’ validated platform, coupled with our in-house FDA and industry experience can help reduce development time and costs associated with companion diagnostic development and approval.

Approved companion diagnostic biomarkers will be incorporated into assays that have been ordered by more than 5,000 oncologists. Tempus can provide a seamless commercialization and reimbursement strategy at launch.